Effects Of GW876008 On The Bowel In Patients With Irritable Bowel Syndrome

A Phase IIa Pharmacodynamic Study of Antagonism of Irritable Bowel Syndrome (IBS) Symptoms by GW876008, a Corticotrophin Releasing Factor 1 Receptor Antagonist (CRF1-RA)

The purpose of this study is to see if GW876008 in Irritable Bowel Syndrome patients will reverse stress-induced hypersensitivity, by looking at thresholds for perception and pain.

Inclusion criteria:

• Must have irritable bowel syndrome.

Exclusion criteria:

• Subjects who have been taking any medication for the treatment of irritable bowel syndrome within 6 months prior to the start of the study.